As of Nov 19, 2026, 2 of 2 active firms rate OKUR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
OKUR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.35
Range $-0.35 – $-0.35 · 1 analysts · -68% YoY
Next period, 1 analysts expect OnKure Therapeutics, Inc. to earn $-0.35 a share (range $-0.35 – $-0.35), versus $-1.11 a year earlier. Full-year consensus is $-1.61, growing to $-1.63 the year after.
REVENUE · NEXT QUARTER
$166.7K
Range $0 – $500.0K · 1 analysts
Revenue is expected to reach $166.7K (range $0 – $500.0K). Full-year consensus is $125.0K, rising to $666.7K next year.
Top analysts covering OnKure Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OKUR.
#1
Andrew Berens
Leerink Partners · Rank #162
Buy
$33.00+1072.3% to target
Overall win rate
53%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$21.00+646.0% to target
Overall win rate
42%
+ Follow
#3
Leland Gershell
Oppenheimer · Rank #404
Buy
$14.00+397.3% to target
Overall win rate
35%
+ Follow
#4
JM
Jonathan Miller
Evercore ISI
Buy
No targeton OKUR
Coverage
—
+ Follow
#5
MB
Matt Biegler
Oppenheimer
Buy
$30.00+965.7% to target
Coverage
—
+ Follow
OKUR stock forecast FAQ
What is OKUR's average 12-month price target?+
The 2 active firms with a live target average $17.50 for OnKure Therapeutics, Inc. over the next 12 months, ranging from a $21.00 high to a $14.00 low, as of Nov 19, 2026.
Is OKUR stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for OKUR?+
The Street-high target is $21.00 (HC Wainwright & Co.), and the Street-low is $14.00 (Oppenheimer). The average of all 2 active-firm targets is $17.50.
How many active Wall Street firms cover OKUR?+
2 active firms have a recognized rating on OnKure Therapeutics, Inc. as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering OKUR?+
Among analysts who currently cover OKUR, Andrew Berens of Leerink Partners has the strongest overall Quantellect track record (Rank #162). Their current call is Buy with a $33.00 target.
What is OnKure Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.35 per share (range $-0.35 – $-0.35) across 1 analysts. Full-year EPS is projected at $-1.61, rising to $-1.63 the following year.
How much revenue is OnKure Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $166.7K (range $0 – $500.0K). Full-year revenue is projected at $125.0K, growing to $666.7K next year.
Have analysts been upgrading or downgrading OKUR lately?+
As of Nov 19, 2026, 2 of 2 active firms rate OKUR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OKUR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.